1. Home
  2. NIU vs BNR Comparison

NIU vs BNR Comparison

Compare NIU & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niu Technologies

NIU

Niu Technologies

HOLD

Current Price

$3.06

Market Cap

223.8M

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$21.20

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIU
BNR
Founded
2014
2014
Country
China
China
Employees
N/A
N/A
Industry
Auto Manufacturing
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.8M
252.7M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
NIU
BNR
Price
$3.06
$21.20
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
342.1K
32.6K
Earning Date
05-18-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.54
$111.65
Revenue Next Year
$17.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.71
$2.18
52 Week High
$5.67
$41.72

Technical Indicators

Market Signals
Indicator
NIU
BNR
Relative Strength Index (RSI) 50.11 55.95
Support Level $2.99 $19.72
Resistance Level $3.22 $23.42
Average True Range (ATR) 0.12 1.43
MACD 0.05 0.91
Stochastic Oscillator 70.93 81.30

Price Performance

Historical Comparison
NIU
BNR

About NIU Niu Technologies

Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: